

Giovanna Cutrona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3992591/publications.pdf>

Version: 2024-02-01

170
papers

3,965
citations

126858

33
h-index

149623

56
g-index

173
all docs

173
docs citations

173
times ranked

5139
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. <i>Hematological Oncology</i> , 2022, 40, 41-48. | 0.8 | 5 |
| 2 | MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. <i>Blood Advances</i> , 2022, 6, 5593-5612. | 2.5 | 3 |
| 3 | Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499. | 1.1 | 5 |
| 4 | Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171. | 2.0 | 10 |
| 5 | Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. <i>Cell Reports</i> , 2021, 34, 108845. | 2.9 | 3 |
| 6 | Validation of the Alternative International Prognostic Score (AIPS): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol. <i>European Journal of Haematology</i> , 2021, 106, 831-835. | 1.1 | 6 |
| 7 | TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310. | 2.0 | 8 |
| 8 | Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272. | 2.0 | 3 |
| 9 | Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2969-2978. | 2.0 | 9 |
| 10 | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621. | 1.3 | 6 |
| 11 | Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. <i>Cells</i> , 2021, 10, 98. | 1.8 | 23 |
| 12 | Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNF α , IL-6 and IL-11 cytokines. <i>Haematologica</i> , 2021, 106, 2598-2612. | 1.7 | 9 |
| 13 | An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 29-38. | 0.9 | 3 |
| 14 | Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. <i>Scientific Reports</i> , 2020, 10, 16519. | 1.6 | 11 |
| 15 | Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383. | 1.3 | 50 |
| 16 | Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. <i>Scientific Reports</i> , 2020, 10, 18427. | 1.6 | 13 |
| 17 | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92. | 2.8 | 7 |
| 18 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869. | 0.6 | 86 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 869-880. | 1.9 | 10 |
| 20 | NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespective of Cytogenetic Groups or Clinical Outcome. <i>Non-coding RNA</i> , 2020, 6, 11. | 1.3 | 11 |
| 21 | Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. <i>Molecular Medicine</i> , 2020, 26, 25. | 1.9 | 17 |
| 22 | Frequency and clinical relevance of coding and noncoding <i>NOTCH1</i> mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408. | 0.8 | 5 |
| 23 | A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620. | 1.7 | 15 |
| 24 | Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859. | 1.2 | 18 |
| 25 | International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278. | 0.2 | 1 |
| 26 | INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). <i>Hematological Oncology</i> , 2019, 37, 81-82. | 0.8 | 1 |
| 27 | Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing. <i>Blood Cancer Journal</i> , 2019, 9, 21. | 2.8 | 10 |
| 28 | Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth. <i>International Journal of Molecular Sciences</i> , 2019, 20, 292. | 1.8 | 10 |
| 29 | PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH "BORDERLINE" PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. <i>HemaSphere</i> , 2019, 3, 134-135. | 1.2 | 0 |
| 30 | Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873. | 3.3 | 8 |
| 31 | Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 13 |
| 32 | Comparison between the CLL-IPI and the Barcelona prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37. | 2.0 | 18 |
| 33 | A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2018, 103, e531-e536. | 1.7 | 24 |
| 34 | Predictive value of the CLL-IPI in CLL patients receiving chemoimmunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706. | 1.1 | 8 |
| 35 | Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219. | 2.0 | 15 |
| 36 | A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. <i>Leukemia</i> , 2017, 31, 1894-1904. | 3.3 | 33 |
| 38 | Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. <i>Scientific Reports</i> , 2017, 7, 14159. | 1.6 | 14 |
| 39 | Toll-like receptor 9 stimulation can induce β_2 -microglobulin expression and IgM secretion in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017, 102, 1901-1912. | 1.7 | 18 |
| 40 | Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. <i>Blood Cancer Journal</i> , 2017, 7, e513-e513. | 2.8 | 5 |
| 41 | Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia. <i>Current Molecular Medicine</i> , 2017, 17, 24-33. | 0.6 | 6 |
| 42 | Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016, 128, 2093-2095. | 0.6 | 52 |
| 43 | lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. <i>Blood Cancer Journal</i> , 2016, 6, e468-e468. | 2.8 | 47 |
| 44 | The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016, 91, 1090-1095. | 2.0 | 58 |
| 45 | Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€œCLLâ€œ study. <i>European Journal of Haematology</i> , 2016, 96, 36-45. | 1.1 | 7 |
| 46 | A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). <i>Clinical Immunology</i> , 2016, 172, 52-60. | 1.4 | 4 |
| 47 | A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2016, 30, 1440-1443. | 3.3 | 28 |
| 48 | Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2015, 10, e0134706. | 1.1 | 16 |
| 49 | Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. <i>Leukemia Research</i> , 2015, 39, 840-845. | 0.4 | 12 |
| 50 | Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. <i>Haematologica</i> , 2015, 100, 1460-1468. | 1.7 | 19 |
| 51 | Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158. | 0.6 | 23 |
| 52 | A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 90-100. | 1.3 | 18 |
| 53 | Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015, 168, 455-459. | 1.2 | 9 |
| 54 | Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. <i>PLoS ONE</i> , 2015, 10, e0118801. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis. <i>Blood</i> , 2015, 126, 1729-1729. | 0.6 | 0 |
| 56 | A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2015, 126, 2930-2930. | 0.6 | 0 |
| 57 | Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression. <i>Blood</i> , 2015, 126, 616-616. | 0.6 | 1 |
| 58 | Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€œCLL1â€œGISL study. <i>American Journal of Hematology</i> , 2014, 89, 743-750. | 2.0 | 14 |
| 59 | Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 264-273. | 1.5 | 10 |
| 60 | Highâ€œthroughput sequencing for the identification of <i><sc>NOTCH</sc>1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014, 165, 629-639. | 1.2 | 52 |
| 61 | Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 612-621. | 1.5 | 38 |
| 62 | microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. <i>Clinical Cancer Research</i> , 2014, 20, 4141-4153. | 3.2 | 52 |
| 63 | Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. <i>Haematologica</i> , 2014, 99, 1078-1087. | 1.7 | 43 |
| 64 | Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3314-3314. | 0.6 | 0 |
| 65 | Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. <i>BMC Medical Genomics</i> , 2013, 6, 27. | 0.7 | 73 |
| 66 | Total body computed tomography scan in the initial workâ€œup of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€œCLL1â€œGISL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544. | 2.0 | 10 |
| 67 | Chromosome 2p gain in monoclonal Bâ€œcell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 24-31. | 2.0 | 27 |
| 68 | The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. <i>Leukemia Research</i> , 2013, 37, 943-947. | 0.4 | 9 |
| 69 | Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. <i>Clinical Cancer Research</i> , 2013, 19, 5890-5900. | 3.2 | 60 |
| 70 | Igs Expressed by Chronic Lymphocytic Leukemia B Cells Show Limited Binding-Site Structure Variability. <i>Journal of Immunology</i> , 2013, 190, 5771-5778. | 0.4 | 21 |
| 71 | External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 1177-1185. | 2.0 | 15 |
| 72 | Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen. <i>Molecular Medicine</i> , 2013, 19, 294-302. | 1.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications. Blood, 2013, 122, 1622-1622. | 0.6 | 0 |
| 74 | MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 4172-4172. | 0.6 | 3 |
| 75 | Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and Microrna Transcriptional Profile. Blood, 2013, 122, 1616-1616. | 0.6 | 1 |
| 76 | Prognostic factors in CLL. Leukemia Supplements, 2012, 1, S29-S30. | 0.1 | 4 |
| 77 | The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis. Blood, 2012, 120, 3889-3889. | 0.6 | 0 |
| 78 | BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis. Blood, 2012, 120, 3934-3934. | 0.6 | 0 |
| 79 | 1.2 Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of CLL. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S141-S142. | 0.2 | 0 |
| 80 | Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. Molecular Medicine, 2011, 17, 834-839. | 1.9 | 9 |
| 81 | Mutation Pattern of Paired Immunoglobulin Heavy and Light Variable Domains in Chronic Lymphocytic Leukemia B Cells. Molecular Medicine, 2011, 17, 1188-1195. | 1.9 | 11 |
| 82 | Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313. | 1.1 | 36 |
| 83 | The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361. | 0.6 | 45 |
| 84 | CD38 and chronic lymphocytic leukemia: a decade later. Blood, 2011, 118, 3470-3478. | 0.6 | 181 |
| 85 | Epigenetic mechanisms regulate \hat{I}^{NP73} promoter function in human tonsil B cells. Molecular Immunology, 2011, 48, 408-414. | 1.0 | 6 |
| 86 | Multiplex ligationâ€dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. Genes Chromosomes and Cancer, 2011, 50, 726-734. | 1.5 | 24 |
| 87 | Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics, 2011, 6, 188-194. | 1.3 | 58 |
| 88 | Abstract 1229: Prognostic significance of telomere length in B-chronic lymphocytic leukemia patients in early stage disease. , 2011, , . | | 0 |
| 89 | Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY. Blood, 2011, 118, 2837-2837. | 0.6 | 0 |
| 90 | Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,. Blood, 2011, 118, 3890-3890. | 0.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Heterogeneous expression and function of IL-21R and susceptibility to IL-21 γ -mediated apoptosis in follicular lymphoma cells. <i>Experimental Hematology</i> , 2010, 38, 373-383. | 0.2 | 22 |
| 92 | Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010, 85, 314-320. | 1.1 | 23 |
| 93 | Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010, 34, e217-e218. | 0.4 | 3 |
| 94 | More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2010, 34, e326-e328. | 0.4 | 2 |
| 95 | Prognostic relevance of <i>in vitro</i> response to cell stimulation via surface IgD in binet stage a CLL. <i>British Journal of Haematology</i> , 2010, 149, 160-163. | 1.2 | 17 |
| 96 | Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion. <i>Clinical Cancer Research</i> , 2010, 16, 5641-5653. | 3.2 | 52 |
| 97 | The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ + λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients. <i>Blood</i> , 2010, 116, 2437-2437. | 0.6 | 1 |
| 98 | Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study.. <i>Blood</i> , 2010, 116, 4613-4613. | 0.6 | 0 |
| 99 | Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. <i>Blood</i> , 2010, 116, 1360-1360. | 0.6 | 2 |
| 100 | Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group. <i>Blood</i> , 2010, 116, 2423-2423. | 0.6 | 0 |
| 101 | Serum level of CD26 predicts time to first treatment in early B γ -chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009, 83, 208-214. | 1.1 | 8 |
| 102 | CD26 expression in mature B γ -cell neoplasia: its possible role as a new prognostic marker in B γ -CLL. <i>Hematological Oncology</i> , 2009, 27, 140-147. | 0.8 | 46 |
| 103 | Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 146, 44-53. | 1.2 | 50 |
| 104 | PNAE $\frac{1}{4}$ can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. <i>Cancer Gene Therapy</i> , 2009, 16, 786-793. | 2.2 | 10 |
| 105 | Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 162-165. | 0.4 | 16 |
| 106 | Predictive value of β 2-microglobulin (β 2-m) levels in chronic lymphocytic leukemia since Binet A stages. <i>Haematologica</i> , 2009, 94, 887-888. | 1.7 | 37 |
| 107 | Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative.. <i>Blood</i> , 2009, 114, 1259-1259. | 0.6 | 0 |
| 108 | External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience.. <i>Blood</i> , 2009, 114, 2375-2375. | 0.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study.. <i>Blood</i> , 2009, 114, 2341-2341. | 0.6 | 0 |
| 110 | Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2008, 88, 374-380. | 0.7 | 12 |
| 111 | Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 781-793. | 1.5 | 59 |
| 112 | Nonjudicious Dispensing of Antibiotics by Drug Stores in Pratumthani, Thailand. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 572-575. | 1.0 | 54 |
| 113 | Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 62-67. | 0.6 | 4 |
| 114 | The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. <i>Blood</i> , 2008, 111, 517-524. | 0.6 | 104 |
| 115 | Constitutive expression of IL-12R β 2 on human multiple myeloma cells delineates a novel therapeutic target. <i>Blood</i> , 2008, 112, 750-759. | 0.6 | 38 |
| 116 | Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. <i>Haematologica</i> , 2008, 93, 413-422. | 1.7 | 42 |
| 117 | Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4187-4187. | 0.6 | 1 |
| 118 | Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers.. <i>Blood</i> , 2008, 112, 1061-1061. | 0.6 | 0 |
| 119 | Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4158-4158. | 0.6 | 9 |
| 120 | Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 1062-1062. | 0.6 | 0 |
| 121 | B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. <i>Journal of Clinical Pathology</i> , 2007, 60, 627-632. | 1.0 | 6 |
| 122 | The Peptide Nucleic Acid Targeted to a Regulatory Sequence of the Translocated c-myc Oncogene in Burkitt's Lymphoma Lacks Immunogenicity: Follow-Up Characterization of PNA β 4-NLS. <i>Oligonucleotides</i> , 2007, 17, 146-150. | 2.7 | 22 |
| 123 | Lack of mutagenicity and clastogenicity of PNA β 4-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2007, 628, 129-137. | 0.9 | 5 |
| 124 | CD5 ⁺ B cells with the features of subepithelial B cells found in human tonsils. <i>European Journal of Immunology</i> , 2007, 37, 2138-2147. | 1.6 | 17 |
| 125 | Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 1575-1578. | 0.4 | 25 |
| 126 | Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. <i>Cancer Gene Therapy</i> , 2007, 14, 220-226. | 2.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3093-3093. | 0.6 | 0 |
| 128 | The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features.. Blood, 2007, 110, 2077-2077. | 0.6 | 0 |
| 129 | CD26 Expression in Mature B-Cell Neoplasia: Its Possible Role as a New Prognostic Marker in B-CLL.. Blood, 2007, 110, 4670-4670. | 0.6 | 0 |
| 130 | Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood, 2006, 107, 3708-3715. | 0.6 | 107 |
| 131 | B lymphocytes in humans express ZAP-70 when activated in vivo. European Journal of Immunology, 2006, 36, 558-569. | 1.6 | 60 |
| 132 | Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2786-2786. | 0.6 | 0 |
| 133 | Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2328-2328. | 0.6 | 1 |
| 134 | Therapeutically Promising PNA Complementary to a Regulatory Sequence for c-myc: Pharmacokinetics in an Animal Model of Human Burkitt's Lymphoma. Oligonucleotides, 2005, 15, 85-93. | 2.7 | 29 |
| 135 | In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation, 2005, 115, 755-764. | 3.9 | 515 |
| 136 | The Response to Surface IgM and IgD Cross-Linking Defines Different Groups of B-CLL.. Blood, 2005, 106, 177-177. | 0.6 | 0 |
| 137 | Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica, 2003, 88, 864-73. | 1.7 | 16 |
| 138 | Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer. Cancer Research, 2003, 63, 6144-8. | 0.4 | 32 |
| 139 | CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. British Journal of Cancer, 2002, 86, 1776-1785. | 2.9 | 36 |
| 140 | Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood, 2002, 99, 2277-2278. | 0.6 | 17 |
| 141 | Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 2001, 97, 2528-2529. | 0.6 | 23 |
| 142 | Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 2001, 7, 807-813. | 15.2 | 88 |
| 143 | Retinoic acid induces persistent, RAR γ -mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines. , 2000, 86, 375-384. | | 21 |
| 144 | Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. International Journal of Cancer, 2000, 88, 744-750. | 2.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. <i>Nature Biotechnology</i> , 2000, 18, 300-303. | 9.4 | 229 |
| 146 | Late Epstein-Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient. <i>Haematologica</i> , 2000, 85, 256-62. | 1.7 | 28 |
| 147 | Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. <i>Blood</i> , 1999, 94, 3067-3076. | 0.6 | 66 |
| 148 | Apoptosis Induced by Crosslinking of CD4 on Activated Human B Cells. <i>Cellular Immunology</i> , 1999, 193, 80-89. | 1.4 | 11 |
| 149 | Identification of HSP-60 as the specific antigen of IgM produced by BRG-lymphoma cells. <i>Electrophoresis</i> , 1999, 20, 1092-1097. | 1.3 | 2 |
| 150 | Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. <i>Blood</i> , 1999, 94, 3067-3076. | 0.6 | 1 |
| 151 | Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. <i>Blood</i> , 1999, 94, 3067-76. | 0.6 | 27 |
| 152 | Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. <i>International Journal of Oncology</i> , 1997, 11, 1203-8. | 1.4 | 1 |
| 153 | C-Myc Proto-oncogene Expression by Germinal Center B Cells Isolated from Human Tonsils. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 436-438. | 1.8 | 3 |
| 154 | The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein. <i>European Journal of Immunology</i> , 1997, 27, 234-238. | 1.6 | 23 |
| 155 | Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal-myc and VDJ rearrangements. <i>Journal of Molecular Biology</i> , 1997, 73, 816-821. | | 6 |
| 156 | The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. <i>Haematologica</i> , 1997, 82, 542-9. | 1.7 | 16 |
| 157 | Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. <i>Blood</i> , 1996, 88, 599-608. | 0.6 | 20 |
| 158 | Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. <i>Journal of Virology</i> , 1996, 68, 810-816. | | 8 |
| 159 | Production of Inflammatory Cytokines by Epstein-Barr Virus (EBV)-Infected Lymphoblastoid Cell Lines Spontaneously Originated from the Peripheral Blood of Patients with Human Immunodeficiency Virus (HIV) Infection. <i>Clinical Immunology and Immunopathology</i> , 1995, 77, 162-171. | 2.1 | 7 |
| 160 | Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. <i>Journal of Experimental Medicine</i> , 1995, 181, 699-711. | 4.2 | 55 |
| 161 | A Retinoic Acid Resistant HL-60 Cell Clone Sensitive to N-(4-hydroxyphenyl) Retinamide-Mediated Clonal Growth Inhibition. <i>Leukemia and Lymphoma</i> , 1995, 17, 175-180. | 0.6 | 8 |
| 162 | A Retinoic Acid Resistant HL-60 Cell Clone Sensitive to N-(4-hydroxyphenyl) Retinamide-Mediated Clonal Growth Inhibition. <i>Leukemia and Lymphoma</i> , 1995, 17, 155-161. | 0.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Transforming growth factor beta-1 (TGF- β 1) released by an Epstein-Barr virus (EBV) positive spontaneous lymphoblastoid cell line from a patient with Kostmann's congenital neutropenia inhibits the growth of normal committed haemopoietic progenitors in vitro. <i>British Journal of Haematology</i> , 1993, 85, 684-691. | 1.2 | 4 |
| 164 | H and L Ferritin Gene Expression in U937 Cells Induced to Macrophage Differentiation. <i>Leukemia and Lymphoma</i> , 1993, 12, 109-115. | 0.6 | 4 |
| 165 | Cytogenetic Rearrangement of C-MYC Oncogene Occurs Prior to Infection with Epstein-Barr Virus in the Monoclonal Malignant B Cells From an AIDS Patient. <i>Leukemia and Lymphoma</i> , 1993, 9, 157-164. | 0.6 | 13 |
| 166 | Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. <i>Blood</i> , 1991, 78, 797-804. | 0.6 | 27 |
| 167 | Cellular and Molecular Characterization of Two Cases of Castleman's Disease, Plasma Cell Variant. <i>Leukemia and Lymphoma</i> , 1991, 5, 391-396. | 0.6 | 0 |
| 168 | Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. <i>Blood</i> , 1991, 78, 797-804. | 0.6 | 0 |
| 169 | Studies on the oncogenic potential of epstein-barr-virus (EBV)-infected B cells in aids-related disorders. <i>International Journal of Cancer</i> , 1989, 44, 78-82. | 2.3 | 6 |
| 170 | Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 4 |